葡萄糖依赖性促胰岛素多肽/胰高血糖素样肽-1双受体激动剂在血糖控制中的作用研究进展

Research progresson the role of glucose-dependent insulinotropic ploypeptide/glucagon-like peptide-1 dual receptor agonists in blood glucose control

葡萄糖依赖性促胰岛素多肽(glucose-dependent insulinotropic ploypeptide,GIP)及胰高血糖素样肽(glucagon-like peptide,GLP)-1是两种主要的肠促胰岛素,二者均能增加葡萄糖依赖的胰岛素分泌,发挥降糖作用。近年来,GLP-1受体激动剂对2型糖尿病(diabetes mellitus type 2,T2DM)的疗效得到广泛认可,但关于GIP对T2DM的疗效仍未完全明确。当GIP与GLP-1在单分子双重激动剂中结合时,可表现出显著协同作用。现主要概述GIP/GLP-1双受体激动剂在T2DM患者血糖控制中的作用,及从临床前研究和临床研究中获得的新发现,旨在为临床提供参考。

Glucose-dependent insulinotropic ploypeptide(GIP)and glucagon-like peptide(GLP)-1 are two main types of incretin.Both of them can increase glucose-dependent insulin secretion and play a hypoglycemic role.In recent years,the efficacy of GLP-1 receptor agonists for diabetes mellitus type 2(T2DM)has been widely recognized,but the effect of GIP on T2DM is still unclear.When GIP is combined with GLP-1 in a single molecule double agonist,it can show a significant synergistic effect.This article summarized the role of GIP/GLP-1 dual receptor agonists in glycemic control in patients with T2DM and the new findings from preclinical and clinical studies to provide reference for clinical practice.